Pulmonary infections involve the lungs and are frequently due to inhalation of a pathogen. Pneumonia is a common disease and is of special consideration in individuals with compromised immune systems. While current therapies are typically able to combat lethal disease, the rise of antimicrobial resistant strains of bacteria requires further research to identify novel therapies. Our pulmonary studies allow for in vivo screening of antimicrobial activity to rapidly identify the most promising therapies.

Procedure
We have established a pulmonary infection model in both mice and rats in which animals are challenged with a pathogen via intranasal (IN) or intratracheal (IT) instillation. Animals may be administered test article via nebulization, oral gavage (PO), intranasal (IN) or intratracheal (IT) instillation, or intravenous (IV), intraperitoneal (IP), intramuscular (IM), or subcutaneous (SC) injection. Each study parameter (animal strain, pathogen, comparator(s), and dosing schedule) can be customized to meet client needs.

Endpoints for this study include mortality tracking and CFU burden in harvested organs and/or blood. Pharmacokinetic profiling, blood chemistry, tissue harvests, and histology are available upon request.

Sample Data

Pathogens

TransPharm has validated a pulmonary model using the following pathogens:

• Acinetobacter baumannii
  • ATCC 17961
• Aspergillus fumigatus
  • ATCC 13073
• Cryptococcus neoformans
  • ATCC 24067
• Haemophilus influenzae 
  • 54A1218, non-typeable
• Klebsiella pneumoniae
  • ATCC 43816
• Pseudomonas aeruginosa
  • ATCC 15692
  • ATCC 27853
• Staphylococcus aureus (MRSA)
  • ATCC 33591
  • ATCC BAA-1556
  • USA300
• Streptococcus pneumoniae
  • ATCC 10813
  • ATCC 70067
  • D39
  • SV-1
  • 402J1095

Additional validations are available upon request.